Connor Clark & Lunn Investment Management Ltd. Purchases 21,764 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Connor Clark & Lunn Investment Management Ltd. grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 466.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,425 shares of the company's stock after buying an additional 21,764 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.09% of Medpace worth $8,821,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in MEDP. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Medpace in the 3rd quarter worth about $3,098,000. Lindenwold Advisors INC grew its position in Medpace by 1.6% during the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company's stock valued at $676,000 after purchasing an additional 32 shares in the last quarter. Joseph Group Capital Management increased its stake in Medpace by 20.6% in the 3rd quarter. Joseph Group Capital Management now owns 3,045 shares of the company's stock valued at $1,016,000 after buying an additional 520 shares during the period. Thrivent Financial for Lutherans lifted its position in Medpace by 61.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 14,430 shares of the company's stock worth $4,817,000 after buying an additional 5,484 shares in the last quarter. Finally, Mutual of America Capital Management LLC boosted its stake in shares of Medpace by 1.9% during the 3rd quarter. Mutual of America Capital Management LLC now owns 13,738 shares of the company's stock valued at $4,586,000 after buying an additional 255 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Down 1.2 %

Medpace stock traded down $4.07 during midday trading on Friday, hitting $337.75. 351,390 shares of the stock were exchanged, compared to its average volume of 285,250. Medpace Holdings, Inc. has a 52 week low of $268.80 and a 52 week high of $459.77. The stock has a market capitalization of $10.50 billion, a PE ratio of 30.32, a P/E/G ratio of 1.74 and a beta of 1.37. The company has a fifty day simple moving average of $340.42 and a two-hundred day simple moving average of $373.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. The company's revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.22 earnings per share. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on MEDP shares. Jefferies Financial Group downgraded Medpace from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $415.00 to $345.00 in a report on Wednesday, September 25th. UBS Group downgraded shares of Medpace from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. StockNews.com cut Medpace from a "buy" rating to a "hold" rating in a research report on Friday, September 27th. William Blair reissued an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Finally, Baird R W cut Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $380.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.